Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-ß/d and PPAR-?. Future cardiology Han, L., Shen, W., Bittner, S., Kraemer, F. B., Azhar, S. 2017

Abstract

The PPARs are a subfamily of three ligand-inducible transcription factors, which belong to the superfamily of nuclear hormone receptors. In mammals, the PPAR subfamily consists of three members: PPAR-a, PPAR-ß/d and PPAR-?. PPARs control the expression of a large number of genes involved in metabolic homeostasis, lipid, glucose and energy metabolism, adipogenesis and inflammation. PPARs regulate a large number of metabolic pathways that are implicated in the pathogenesis of metabolic diseases such as metabolic syndrome, Type 2 diabetes mellitus, nonalcoholic fatty liver disease and cardiovascular disease. The aim of this review is to provide up-to-date information about the biochemical and metabolic actions of PPAR-ß/d and PPAR-?, the therapeutic potential of their agonists currently under clinical development and the cardiovascular disease outcome of clinical trials of PPAR-? agonists, pioglitazone and rosiglitazone.

View details for DOI 10.2217/fca-2017-0019

View details for PubMedID 28581362